Publicacións en colaboración con investigadores/as de Instituto Nacional de Cardiología (21)

2024

  1. Protocolized Natriuresis-Guided Decongestion Improves Diuretic Response: The Multicenter ENACT-HF Study

    Circulation: Heart Failure, Vol. 17, Núm. 1, pp. E011105

2023

  1. Impact of Complete Revascularization in the ISCHEMIA Trial

    Journal of the American College of Cardiology, Vol. 82, Núm. 12, pp. 1175-1188

  2. Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial

    JACC: Heart Failure, Vol. 11, Núm. 12, pp. 1729-1738

2022

  1. Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial

    American Heart Journal, Vol. 248, pp. 72-83

  2. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases

    Heart Rhythm, Vol. 19, Núm. 7, pp. e1-e60

  3. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Vol. 24, Núm. 8, pp. 1307-1367

  4. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases

    Journal of Arrhythmia, Vol. 38, Núm. 4, pp. 491-553

  5. Left atrial volume changes during exercise stress echocardiography in heart failure and hypertrophic cardiomyopathy

    Hellenic Journal of Cardiology, Vol. 67, pp. 9-18

  6. Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation

    New England Journal of Medicine, Vol. 387, Núm. 11, pp. 978-988

2021

  1. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

    New England Journal of Medicine, Vol. 384, Núm. 2, pp. 105-116

  2. Current use of cardiac magnetic resonance in tertiary referral centres for the diagnosis of cardiomyopathy: The ESC EORP Cardiomyopathy/Myocarditis Registry

    European Heart Journal Cardiovascular Imaging, Vol. 22, Núm. 7, pp. 781-789

  3. Feasibility and functional correlates of left atrial volume changes during stress echocardiography in chronic coronary syndromes

    International Journal of Cardiovascular Imaging, Vol. 37, Núm. 3, pp. 953-964

  4. MYH7 p.Glu903Gln Is a Pathogenic Variant Associated With Hypertrophic Cardiomyopathy

    Circulation: Genomic and Precision Medicine, Vol. 14, Núm. 5, pp. E003476

  5. Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study

    ESC Heart Failure, Vol. 8, Núm. 6, pp. 4685-4692

  6. Stress echo 2030: The novel ABCDE-(FGLPR) protocol to define the future of imaging

    Journal of Clinical Medicine, Vol. 10, Núm. 16

2020

  1. Initial invasive or conservative strategy for stable coronary disease

    New England Journal of Medicine, Vol. 382, Núm. 15, pp. 1395-1407

  2. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials

    European Journal of Heart Failure, Vol. 22, Núm. 11, pp. 2160-2171

  3. The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation

    American Heart Journal, Vol. 225, pp. 69-77

2017

  1. A survey of anatomical items relevant to the practice of rheumatology: pelvis, lower extremity, and gait

    Clinical Rheumatology, Vol. 36, Núm. 12, pp. 2813-2819

2012

  1. Quorum quenching quandary: Resistance to antivirulence compounds

    ISME Journal, Vol. 6, Núm. 3, pp. 493-501